144 related articles for article (PubMed ID: 26687836)
1. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
[TBL] [Abstract][Full Text] [Related]
2. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
Heinrich MC; Rankin C; Blanke CD; Demetri GD; Borden EC; Ryan CW; von Mehren M; Blackstein ME; Priebat DA; Tap WD; Maki RG; Corless CL; Fletcher JA; Owzar K; Crowley JJ; Benjamin RS; Baker LH
JAMA Oncol; 2017 Jul; 3(7):944-952. PubMed ID: 28196207
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.
Serrano C; Bauer S; Gómez-Peregrina D; Kang YK; Jones RL; Rutkowski P; Mir O; Heinrich MC; Tap WD; Newberry K; Grassian A; Shi H; Bialick S; Schöffski P; Pantaleo MA; von Mehren M; Trent JC; George S
Ann Oncol; 2023 Jul; 34(7):615-625. PubMed ID: 37105265
[TBL] [Abstract][Full Text] [Related]
4. Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H.
Revheim ME; Kristian A; Malinen E; Bruland ØS; Berner JM; Holm R; Joensuu H; Seierstad T
Acta Oncol; 2013 May; 52(4):776-82. PubMed ID: 23480638
[TBL] [Abstract][Full Text] [Related]
5. Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry.
Call J; Walentas CD; Eickhoff JC; Scherzer N
BMC Cancer; 2012 Mar; 12():90. PubMed ID: 22429770
[TBL] [Abstract][Full Text] [Related]
6. Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.
Bauer S; Joensuu H
Drugs; 2015 Aug; 75(12):1323-34. PubMed ID: 26187774
[TBL] [Abstract][Full Text] [Related]
7. Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study.
Rubió-Casadevall J; Borràs JL; Carmona-García MC; Ameijide A; Gonzalez-Vidal A; Ortiz MR; Bosch R; Riu F; Parada D; Martí E; Miró J; Sirvent JJ; Galceran J; Marcos-Gragera R
World J Surg Oncol; 2015 Feb; 13():47. PubMed ID: 25885906
[TBL] [Abstract][Full Text] [Related]
8. KIT
Banerjee S; Yoon H; Ting S; Tang CM; Yebra M; Wenzel AT; Yeerna H; Mesirov JP; Wechsler-Reya RJ; Tamayo P; Sicklick JK
Mol Cancer Ther; 2021 Oct; 20(10):2035-2048. PubMed ID: 34376580
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study.
Hompland I; Boye K; Wiedswang AM; Papakonstantinou A; Røsok B; Joensuu H; Bruland Ø
Acta Oncol; 2024 May; 63():288-293. PubMed ID: 38712513
[TBL] [Abstract][Full Text] [Related]
10. The long-term efficacy of imatinib with hepatic resection or other local treatment for gastrointestinal stromal tumours liver metastases: a retrospective cohort study.
Wen H; Huang Y; Huang S; Xiao H; Xie W; Zhou Q; Tan L; Ding Y; Liu X; Yu Y; Song Z; Shen S; Chen Z; Zhang X
Int J Surg; 2024 Apr; 110(4):2151-2161. PubMed ID: 38619177
[TBL] [Abstract][Full Text] [Related]
11. Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: Retrospective analysis of an International Patient Registry.
Stuart E; Banerjee S; de la Torre J; Wang Y; Scherzer N; Burgoyne AM; Parry L; Fanta PT; Ramamoorthy S; Sicklick JK
J Surg Oncol; 2019 Sep; 120(4):715-721. PubMed ID: 31297829
[TBL] [Abstract][Full Text] [Related]
12. Genomic profiling in GIST: Implications in clinical outcome and future challenges.
Calderillo-Ruíz G; Pérez-Yepez EA; García-Gámez MA; Millan-Catalan O; Díaz-Romero C; Ugalde-Silva P; Salas-Benavides R; Pérez-Plasencia C; Carbajal-López B
Neoplasia; 2024 Feb; 48():100959. PubMed ID: 38183711
[TBL] [Abstract][Full Text] [Related]
13. [Gastrointestinal stromal tumors : Where do we stand?].
Wardelmann E; Kuntze A; Voloshin A; Elges S; Trautmann M; Hartmann W
Pathologie (Heidelb); 2024 May; 45(3):223-232. PubMed ID: 38587549
[TBL] [Abstract][Full Text] [Related]
14. Personalized radiomics signature to screen for KIT-11 mutation genotypes among patients with gastrointestinal stromal tumors: a retrospective multicenter study.
Zhang QW; Zhang RY; Yan ZB; Zhao YX; Wang XY; Jin JZ; Qiu QX; Chen JJ; Xie ZH; Lin J; Cao H; Zhou Y; Chen HM; Li XB
J Transl Med; 2023 Oct; 21(1):726. PubMed ID: 37845765
[TBL] [Abstract][Full Text] [Related]
15. REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial.
Martin-Broto J; Valverde C; Hindi N; Vincenzi B; Martinez-Trufero J; Grignani G; Italiano A; Lavernia J; Vallejo A; Tos PD; Le Loarer F; Gonzalez-Campora R; Ramos R; Hernández-Jover D; Gutierrez A; Serrano C; Monteagudo M; Letón R; Robledo M; Moura DS; Martin-Ruiz M; López-Guerrero JA; Cruz J; Fernandez-Serra A; Blay JY; Fumagalli E; Martinez-Marin V
Mol Cancer; 2023 Aug; 22(1):127. PubMed ID: 37559050
[TBL] [Abstract][Full Text] [Related]
16. Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era.
Dermawan JK; Kelly C; Gao Z; Smith S; Jadeja B; Singer S; Tap WD; Chi P; Antonescu CR
Clin Cancer Res; 2023 Oct; 29(19):3974-3985. PubMed ID: 37477937
[TBL] [Abstract][Full Text] [Related]
17. Bioinformatic analysis of KIT juxtamembrane domain mutations in Syrian GIST patients: jigsaw puzzle completed.
Pharaon N; Habbal W; Monem F
J Egypt Natl Canc Inst; 2023 Aug; 35(1):25. PubMed ID: 37574490
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and Prognostic Significance of Expression of B-Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (BMI-1) Gene and Protein in Gastrointestinal Stromal Tumors.
Zhu K; Li K; Yuan DW; Xu G; Kang L; Dang CX; Zhang Y
Med Sci Monit; 2018 Sep; 24():6414-6421. PubMed ID: 30209248
[TBL] [Abstract][Full Text] [Related]
19. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
Zhuang W; Xie JD; Zhou S; Zhou ZW; Zhou Y; Sun XW; Yuan XH; Huang M; Liu S; Xin S; Su QB; Qiu HB; Wang XD
Cancer Med; 2018 Feb; 7(2):317-324. PubMed ID: 29316372
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal stromal tumor in North Africa and the middle east: updates in presentation and management from an 11-year retrospective cohort.
Farhat F; Hussein M; Sbaity E; Alsharm A; Rasul K; Khairallah S; Assi T; Allahverdi N; Othman A; Kattan J
Hosp Pract (1995); 2023 Dec; 51(5):275-287. PubMed ID: 38112178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
